A5003890241- Complement system in diseases
- Renal Diseases and Glomerulopathies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood groups and transfusion
- Substance Abuse Treatment and Outcomes
- Prenatal Substance Exposure Effects
- Racial and Ethnic Identity Research
- Medication Adherence and Compliance
- Bacillus and Francisella bacterial research
- Immune Response and Inflammation
- Migration, Health and Trauma
- Aquaculture disease management and microbiota
- Viral Infections and Outbreaks Research
- Sex work and related issues
- Adolescent Sexual and Reproductive Health
- interferon and immune responses
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Telemedicine and Telehealth Implementation
- COVID-19 and Mental Health
- SARS-CoV-2 and COVID-19 Research
- Adenosine and Purinergic Signaling
- Erythrocyte Function and Pathophysiology
- Blood Coagulation and Thrombosis Mechanisms
University of Kentucky
2024
Kentucky Department of Education
2024
University of Iowa
2017-2022
Renal Research Institute
2020
Factor H (FH), a member of the regulators-of-complement-activation (RCA) family proteins, circulates in human plasma at concentrations 180-420 mg/L where it controls alternative pathway (AP) complement fluid phase and on cell surfaces. When regulatory function FH is impaired, complement-mediated tissue injury inflammation occur, leading to diseases such as atypical hemolytic uremic syndrome (a thrombotic microangiopathy or TMA), C3 glomerulopathy (C3G) monoclonal gammopathy renal...
Therapeutic complement inhibition is a major focus for novel drug development. Of upstream targets, factor D (FD) appealing because it circulates in plasma at low concentrations and has single function: to cleave B generate C3 convertase of the alternative pathway (AP). Mice with targeted deletion H (FH; Cfh-/- mice) develop glomerulopathy (C3G) due uncontrolled AP activity. To assess impact FD inhibition, we studied Cfd-/- mice. We show that C3G mice not rescued by removing FD. used serum...
C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are two rare diseases caused by dysregulated activity of the alternative pathway complement secondary to presence genetic and/or acquired factors. Complement factor I (FI) is a serine protease that downregulates in fluid phase on cell surfaces conjunction with one its cofactors, H (FH), receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor (MCP/CD46). Because altered FI causally related pathogenesis C3G...
The rise in opioid misuse coincides with increased sexually transmitted infection (STI) and HIV incidence. Transactional sex is an under-researched phenomenon among Black Americans who opioids, may increase their risk of STI or transmission. Given the disproportionate impact epidemic on risks associated misuse, current study aims to investigate sociostructural factors, history violence, sexual factors transactional men women. A sample n = 375 adult Kentuckians reporting completed a survey...
Background: Several studies link racism with drug use disparities among systemically marginalized populations. However, few invite Black Americans to discuss how they perceive racism's impact on their use. Objectives: To examine qualitative accounts from N=40 adults reporting non-medical prescription opioid experiences of and Results: A deductive structural tabular thematic analysis informed by Jones's (Citation2000) levels resulted in two themes: (a) Experiences Racism (subthemes: Denying...